Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Disc Medicine Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IRON
Nasdaq
8731
https://www.discmedicine.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Disc Medicine Inc
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
- May 14th, 2024 2:30 pm
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
- May 13th, 2024 12:00 pm
Disc Medicine Inc (IRON) Reports Q1 2024 Earnings: A Detailed Financial Overview
- May 11th, 2024 9:31 am
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
- May 9th, 2024 12:00 pm
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
- Apr 4th, 2024 5:21 pm
Disc Medicine (IRON) Down on Mixed Results From AURORA Study
- Apr 2nd, 2024 6:24 pm
Disc Medicine Plummets After Placebo Effect Confounds Sunlight Sensitivity Study
- Apr 1st, 2024 8:19 pm
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
- Apr 1st, 2024 12:00 pm
Disc Medicine Inc (IRON) Reports Earnings: A Detailed Look at Fiscal Performance
- Mar 23rd, 2024 9:31 am
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 21st, 2024 12:00 pm
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
- Mar 6th, 2024 9:30 pm
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
- Feb 26th, 2024 1:30 pm
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
- Feb 20th, 2024 1:30 pm
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
- Feb 9th, 2024 2:00 pm
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
- Feb 7th, 2024 1:00 pm
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 10:00 pm
Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
- Dec 20th, 2023 9:30 pm
Insider Sell Alert: Director William White Sells 33,511 Shares of Disc Medicine Inc (IRON)
- Dec 15th, 2023 8:01 pm
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
- Dec 12th, 2023 1:30 am
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
- Dec 11th, 2023 5:00 pm
Scroll